News | April 29, 2007

Aastrom Cleared to Begin Landmark PAD Clinical Trial

April 30, 2007 — Aastrom Biosciences Inc. has announced it has initiated its U.S. Phase IIb prospective, controlled, randomized, double-blind, multicenter clinical trial to treat patients suffering from peripheral arterial disease (PAD). The company will use its Tissue Repair Cell (TRC)-based product to treat critical limb ischemia (CLI) in this patient population.

“This is a landmark study in terms of the number of patients to be enrolled, and the scientific rigor of its design,” said Anthony J. Comerota, M.D., F.A.C.S., F.A.C.C., Director, Jobst Vascular Center and Adjunct Professor at the University of Michigan. “If this therapy proves successful in these critically ill patients, it will have implications beyond the treatment of limb ischemia, which may apply to all ischemic diseases. This is an intuitively attractive treatment concept as it takes advantage of the patients' own cells to restore blood flow and to regenerate blood vessels in patients whose native arterial circulation is thought to be irreversibly damaged.''

Aastrom's double-blind study is expected to enroll 120 patients, randomized into two patient groups, to evaluate the safety and efficacy of the TRC-based product in the treatment of CLI. The treatment group will receive intramuscular injections of the TRC product into the affected limb; the control group will receive intramuscular injections with an electrolyte solution (without cells). Both groups will receive the standard of care appropriate for their medical condition.

Patients from both groups will be followed for a period of 12 months, post-treatment. The primary objective of the clinical trial is to assess the safety of the TRC-based product in CLI patients. Secondary objectives include assessing amputation rates, wound closure and blood flow in the affected limbs, patient quality of life, and the reduction of pain and analgesic use. Once the first 30 patients have completed the 12-month follow-up, Aastrom will analyze the interim results from these patients. Data gathered from this clinical trial will provide the scientific and statistical basis for an anticipated pivotal trial in the vascular regeneration area.

Aastrom initiated patient enrollment in this clinical trial after receiving Investigational New Drug (IND) approval from the U.S. FDA and Institutional Review Board (IRB) approval from several clinical sites. Aastrom will update its Web site as each clinical site, of the anticipated 20 sites, is initiated for patient enrollment.

This is Aastrom's second study evaluating the Company's TRC-based therapy in patients with critical limb ischemia. Aastrom's TRC-based product is also being used in a clinical trial being conducted at the Heart and Diabetes Center North Rhine-Westphalia in Bad Oeynhausen, Germany.

For more information visit

Related Content

News | Peripheral Artery Disease (PAD)| December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI).

The LimFlow Percutaneous Deep Vein Arterialization System (pDVA) converts veins into arteries to restore blood flow in critical limb ischemia (CLI). This image shows how the covered stents used with the system connect to create a new arterial pathway.

News | Peripheral Artery Disease (PAD)| August 02, 2017
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty System
News | Peripheral Artery Disease (PAD)| June 26, 2017
Shockwave Medical recently announced two milestones for its Lithoplasty System for the treatment of calcified plaque in...
Overlay Init